PT  - JOURNAL ARTICLE
AU  - Helsingen, Lise M.
AU  - Løberg, Magnus
AU  - Refsum, Erle
AU  - Gjøstein, Dagrun Kyte
AU  - Wieszczy, Paulina
AU  - Olsvik, Ørjan
AU  - Juul, Frederik E.
AU  - Barua, Ishita
AU  - Jodal, Henriette C.
AU  - Herfindal, Magnhild
AU  - Mori, Yuichi
AU  - Jore, Solveig
AU  - Lund-Johansen, Fridtjof
AU  - Fretheim, Atle
AU  - Bretthauer, Michael
AU  - Kalager, Mette
AU  - ,
TI  - A Randomised Trial of Covid-19 Transmission in Training Facilities
AID  - 10.1101/2020.06.24.20138768
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.24.20138768
4099  - http://medrxiv.org/content/early/2020/11/17/2020.06.24.20138768.short
4100  - http://medrxiv.org/content/early/2020/11/17/2020.06.24.20138768.full
AB  - Background Closed training facilities during the Covid-19 pandemic may negatively impact people’s health and wellbeing. We investigated SARS-CoV-2 virus transmission, Covid-19 and SARS-CoV-2 antibodies attributable to training facilities.Methods We randomised members aged 18 to 64 without relevant comorbidities at five training facilities in Oslo, Norway, to access or no access to their facility. Facilities opened May 22, 2020 for the training arm, applying physical distancing (1 meter for floor exercise, 2 meters for high-intensity classes) and enhanced hand and surface hygiene. We compared SARS-CoV-2 RNA status by self-administered naso-, oropharyngeal and sputum sampling after 14 days; clinical disease through electronic patient records after 21 days; and SARS-CoV-2 antibody status by dried-blood self-sampling after one month. (ClinicalTrials.gov number NCT04406909)Findings 3,764 individuals were randomised; 1,896 in the training and 1,868 in the no-training arm. In the training arm, 81.8% trained at least once, and 38.5% trained ≥six times. Of 3,016 individuals who returned the SARS-CoV-2 RNA tests (80.5%), there was one positive test. The positive individual was randomised to training, but had not used the training facility, and the workplace was identified as transmission source. There were no outpatient visits or hospital admissions due to Covid-19 in either group. Eleven individuals in the training arm (0.8% of tested) and 27 in the no-training arm (2.4% of tested) tested positive for SARS-CoV-2 antibodies (p=0.001).Interpretation Provided good hygiene and physical distancing measures, there was no increased transmission of SARS-CoV-2 at training facilities.Funding Norwegian Research Council, grant no. 312757Competing Interest StatementDr. Lise M. Helsingen reports grants from Norwegian Research Council (grant no. 312757), during the conduct of the study. Dr. Frederik E. Juul reports grants and personal fees from Regional Health Trust of South-East Norway, outside the submitted work. Dr. Yuichi Mori reports personal fees from Olympus Corp., grants from Japan Society for the Promotion of Science, outside the submitted work. Prof. Michael Bretthauer and Prof. Mette Kalager reports non-financial support from Guideline committee memberships for different professional organizations in colorectal cancer screening, grants and non-financial support from Research grants for clinical trials and epidemiology from various academic and public funders (to employer), outside the submitted work. All other authors declare no competing interests Clinical TrialNCT04406909Funding StatementNorwegian Research Council (grant no. 312757)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:South-East Norway IRB, Oslo, NorwayAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available on request in tabulated form.